Corporate Profile

Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases


Nov 29, 2022 at 1:00 PM EST
Dec 1, 2022 at 8:00 AM EST
Dec 7, 2022 at 9:40 AM EST